Britain and America have announced a landmark bilateral deal that will ensure no levies on British drug products being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the NHS. This pledge secures that tariffs on these key goods will remain at nothing for a timeframe of the next three years.
This development comes after earlier statements to significantly raise duties on branded drug products, with increases floated reaching 100%.
"This arrangement with the Britain strengthens the worldwide climate for innovative medicines and establishes long-overdue equity to transatlantic medicine commerce," a release noted.
Economic Importance
Medicines constitute one of the the United Kingdom's most significant goods shipped to the America, which is by far the largest destination for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period prior to the third quarter, the UK sold medicines worth over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that timeframe.
"This guarantee protects jobs, boosts funding and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The pact follows a ongoing row between the drug companies and the ministers over medicine costs and regulatory access.
This friction were heightened by assertions that US patients were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been halted or cancelled, while substantial funding commitments have been announced toward American operations.
The Science Minister stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
